Literature DB >> 18603562

A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron.

Maria Antonietta Melis1, Milena Cau, Rita Congiu, Gabriella Sole, Susanna Barella, Antonio Cao, Mark Westerman, Mario Cazzola, Renzo Galanello.   

Abstract

BACKGROUND: Hepcidin plays a key role in body iron metabolism by preventing the release of iron from macrophages and intestinal cells. Defective hepcidin synthesis causes iron loading, while overproduction results in defective reticuloendothelial iron release and iron absorption. DESIGN AND METHODS: We studied a Sardinian family in which microcytic anemia due to defective iron absorption and utilization is inherited as a recessive character. Five members showed iron deficiency anemia that was not responsive to oral iron and only partially responsive to parenteral iron administration. To investigate the involvement of known genes implicated in iron metabolism we carried out linkage analysis with microsatellite markers mapping close to these genes. Afterwards, a genome-wide search was performed.
RESULTS: No linkage was found between the phenotype of the patients and several known human genes involved in iron metabolism (DMT1, TF, TFRC, ZIRTL, HAMP, HJV). Genome-wide scanning by microsatellites and single nucleotide polymorphisms showed a multipoint LOD score of 5.6 on chromosome 22q12.3-13.1, where the matriptase-2 (also known as transmembrane protease, serine 6 or TMPRSS6) gene is located. Its murine counterpart (Tmprss6) has recently been found to be an essential component of a pathway that detects iron deficiency and suppresses hepcidin production. Sequencing analysis of TMPRSS6 revealed a homozygous causal mutation, predicting a splicing error and a truncated TMPRSS6 protein in affected members. Homozygous subjects had inappropriately elevated levels of serum and urinary hepcidin.
CONCLUSIONS: The findings of this study suggest that the observed TMPRSS6 mutation leads to overproduction of hepcidin and, in turn, to defective iron absorption and utilization. More generally, they confirm in humans the inhibitory effect of matriptase-2 on hepcidin synthesis already demonstrated in mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18603562     DOI: 10.3324/haematol.13342

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  61 in total

1.  Identification of a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels.

Authors:  Irene Pichler; Cosetta Minelli; Serena Sanna; Toshiko Tanaka; Christine Schwienbacher; Silvia Naitza; Eleonora Porcu; Cristian Pattaro; Fabio Busonero; Alessandra Zanon; Andrea Maschio; Scott A Melville; Maria Grazia Piras; Dan L Longo; Jack Guralnik; Dena Hernandez; Stefania Bandinelli; Elmar Aigner; Anthony T Murphy; Victor Wroblewski; Fabio Marroni; Igor Theurl; Carsten Gnewuch; Eric Schadt; Manfred Mitterer; David Schlessinger; Luigi Ferrucci; Derrick R Witcher; Andrew A Hicks; Günter Weiss; Manuela Uda; Peter P Pramstaller
Journal:  Hum Mol Genet       Date:  2010-12-28       Impact factor: 6.150

Review 2.  The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.

Authors:  Toni M Antalis; Marguerite S Buzza; Kathryn M Hodge; John D Hooper; Sarah Netzel-Arnett
Journal:  Biochem J       Date:  2010-06-15       Impact factor: 3.857

3.  The role of ubiquitination in hepcidin-independent and hepcidin-dependent degradation of ferroportin.

Authors:  Ivana De Domenico; Eric Lo; Baoli Yang; Tamara Korolnek; Iqbal Hamza; Diane McVey Ward; Jerry Kaplan
Journal:  Cell Metab       Date:  2011-10-20       Impact factor: 27.287

Review 4.  Genetic variation in hepcidin expression and its implications for phenotypic differences in iron metabolism.

Authors:  Henry K Bayele; Surjit Kaila S Srai
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

Review 5.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 6.  Molecular mechanisms of normal iron homeostasis.

Authors:  An-Sheng Zhang; Caroline A Enns
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

7.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Authors:  Paul J Schmidt; Iva Toudjarska; Anoop K Sendamarai; Tim Racie; Stuart Milstein; Brian R Bettencourt; Julia Hettinger; David Bumcrot; Mark D Fleming
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 8.  Iron-refractory iron deficiency anemia: new molecular mechanisms.

Authors:  Yujie Cui; Qingyu Wu; Yiqing Zhou
Journal:  Kidney Int       Date:  2009-09-23       Impact factor: 10.612

Review 9.  Role of matriptase-2 (TMPRSS6) in iron metabolism.

Authors:  Pauline Lee
Journal:  Acta Haematol       Date:  2009-11-10       Impact factor: 2.195

Review 10.  Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis.

Authors:  Achille Iolascon; Luigia De Falco; Carole Beaumont
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.